newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our cell therapy